製薬・バイオテクノロジー分野におけるウェアラブルデバイス市場規模、シェア、動向、2031年までの世界予測

製薬・バイオテクノロジー分野におけるウェアラブル市場は、2026年の39億8,000万米ドルから2031年には99億7,000万米ドルに成長し、年平均成長率（CAGR）は20.2%に達するとMarketsandMarketsでは予測しています。

この市場は、バイオセンサー、小型化、デジタル化における急速な技術開発によって牽引されています。世界的なデジタル接続の拡大も、ウェアラブル市場の拡大を促進する重要な要因です。国際電気通信連合（ITU）は、2023年に世界中で54億人以上がインターネットを利用していたと報告しています。この広範な接続性により、ウェアラブルデバイスからのデータをクラウド環境にシームレスに統合することが可能になっています。さらに、「All of Us Research Program」では50万人以上の参加者を募っており、その一部は活動レベル、心拍数、睡眠パターンなどのウェアラブルからのデータを提供しています。これは、大規模な生物医学研究や精密医療におけるウェアラブル技術の役割の拡大を反映しています。この成長は、遠隔患者モニタリング（RPM）やデジタルケアソリューションの普及拡大によってさらに後押しされています。米国では、メディケア・メディケイドサービスセンター（CMS）が、2022年の政策拡大後、遠隔生理モニタリングサービスの償還請求が大幅に増加したと報告しました。これは、医療提供者の間でウェアラブルデバイスを用いた医療が広く普及していることを示しています。さらに、センサーの精度向上と多項目モニタリング技術の進歩により、ウェアラブルデバイスは基本的なバイタルサインだけでなく、臨床的に重要なエンドポイントも測定できるようになっています。これにより、医薬品の安全性や治療効果の研究におけるウェアラブルデバイスの活用範囲が拡大しています。

調査範囲

本調査レポートは、製薬・バイオテクノロジー市場におけるウェアラブルデバイスを、製品（スマートウォッチ、フィットネスバンド、スマートリング、持続血糖測定器（CGM）、パッチ、ウェアラブル注射器、その他）、治療領域（心血管疾患（動脈硬化性心血管疾患（ASCVD）／二次予防、心不全（HFREFおよびHFPEF）、高血圧、心房細動（AF）／脳卒中予防、肺高血圧症、構造的心疾患／インターベンショナル心臓病学）、腫瘍（固形腫瘍、血液悪性腫瘍）、糖尿病、メンタルヘルス・行動健康、呼吸器疾患、ライフスタイル・健康改善、神経学、筋骨格系疾患／疼痛管理、女性の健康・生殖健康、その他の疾患）、用途（創薬、臨床試験（第II相、第III相、第IV相）、服薬遵守・行動支援、慢性疾患モニタリング、個別化・予防的デジタル治療）、エンドユーザー別に分類しています。 （製薬・バイオテクノロジー企業、医療提供者・臨床医、その他のエンドユーザー）、および地域（北米、ヨーロッパ、アジア太平洋、ラテンアメリカ、中東・アフリカ）を対象としています。本レポートでは、製薬・バイオテクノロジー市場におけるウェアラブルの成長に影響を与える主要な要因（推進要因、制約要因、課題、機会など）に関する詳細な情報を網羅しています。主要な業界プレーヤーの詳細な分析を行い、事業概要、ソリューション、サービス、主要戦略、契約、パートナーシップ、合意、新製品・サービスの発売、合併・買収、および製薬・バイオテクノロジー市場におけるウェアラブルに関連する最近の動向についての洞察を提供しています。本レポートでは、市場エコシステムにおける新興企業の競合分析も取り上げています。

本レポートを購入する理由

本レポートは、製薬（医薬品開発）・バイオテクノロジー市場におけるウェアラブル機器の市場規模とサブセグメントごとの収益予測値を提供することで、市場リーダーや新規参入企業を支援します。また、競争環境の理解を深め、事業のポジショニングを改善し、適切な市場参入戦略を策定するための洞察力を高めるのに役立ちます。さらに、市場の動向を把握し、主要な市場促進要因、阻害要因、課題、機会に関する情報を提供します。

本レポートは、以下のポイントに関する洞察を提供します。

製薬・バイオテクノロジー分野におけるウェアラブル市場の成長に影響を与える主要な推進要因（価値に基づく患者中心の医療モデルへの移行、継続的な患者モニタリングを必要とする慢性疾患の罹患率の上昇、医療の急速なデジタル化と遠隔医療サービスの拡大）、阻害要因（医療提供者にとっての導入・統合コストの高さ、データプライバシーとサイバーセキュリティへの懸念）、機会（遠隔患者モニタリングと在宅医療モデルの拡大、高度な分析と個別化医療の統合）、および課題（既存の医療ITシステムとの相互運用性の制限、患者の利用率の低さ、デジタルリテラシーの障壁）の分析。

• 製品開発／イノベーション：製薬（医薬品開発）・バイオテクノロジー分野におけるウェアラブル市場における今後の技術、研究開発活動、新製品・新サービスの発売に関する詳細な洞察。
• 市場開発：有望な市場に関する包括的な情報。本レポートは、様々な地域における医薬品・バイオテクノロジー分野におけるウェアラブル市場を分析しています。
• 市場の多様化：製薬・バイオテクノロジー分野におけるウェアラブルデバイス市場における新製品・サービス、未開拓地域、最新動向、投資に関する包括的な情報。
• 競合分析：製薬・バイオテクノロジー分野におけるウェアラブルデバイス市場において、BD（米国）、アボット（米国）、マシモ（米国）、デクスコム（米国）、メドトロニック（アイルランド）などの主要企業の市場シェア、成長戦略、サービス提供内容を詳細に分析。

Report Description

The wearables in pharma & biotech market is projected to reach USD 9.97 billion by 2031 from USD 3.98 billion in 2026, at a CAGR of 20.2%. The market is driven by rapid technological developments in biosensors, miniaturization, and digitization. Increasing global digital connectivity is another significant facilitator of the expanding wearable market. The International Telecommunication Union reported that over 5.4 billion people worldwide were using the internet in 2023. This widespread connectivity is enabling the seamless integration of data from wearable devices into cloud environments. Additionally, the All of Us Research Program has recruited more than 500,000 participants, some of whom are contributing data from wearables, including activity levels, heart rate, and sleep patterns. This reflects the growing role of wearable technology in large-scale biomedical research and precision medicine. This growth is further supported by the increasing adoption of remote patient monitoring (RPM) and digital care solutions. In the US, the Centers for Medicare & Medicaid Services reported a substantial increase in reimbursement claims for remote physiological monitoring services following the expansion of the policy in 2022. This indicates widespread adoption of wearable-derived care among healthcare providers. In addition, developments in the accuracy of sensors and multi-parameter monitoring are allowing wearables to measure clinically significant endpoints beyond basic vital signs. This is expanding the scope of wearables in drug safety and therapeutic studies.

“By product, continuous glucose monitors (CGMs) segment to account for largest market share”

The product segment is divided into smartwatches, fitness bands, smart rings, continuous glucose monitors (CGMs), patches, wearable injectors, and others. The CGMs segment has a large market share due to the high level of support from clinical guidelines, increasing scope of eligible patients, and the ability of the devices to be used with the most advanced diabetic management systems. The American Diabetes Association recommends the use of CGMs for a broad population of diabetic patients, as per the 2024 Standards of Care, thereby increasing the scope of the market. Furthermore, the availability of reimbursement schemes for hundreds of thousands of patients through the National Health Service has also helped the market expand in the region. In addition, approvals by the Food and Drug Administration for interoperable CGMs used in conjunction with insulin delivery systems have also helped the market expand in the region. The devices also provide up to 288 glucose readings in a day, making them highly valuable in the market .

“By end user, pharmaceutical and biotech companies accounted for largest market share in 2025”

Pharmaceutical and biotech companies dominated the market for wearables in the pharma & biotech market in terms of market share in 2025. This is mainly attributed to the complexity of clinical trials, where pharmaceutical and biotech companies require wearable technologies for data collection. According to a study by the Tufts Center for the Study of Drug Development, clinical trial protocols currently involve more than 20 endpoints on average, thus increasing the requirement for data collection. Wearable technologies are increasingly being used in this context. Furthermore, large-scale research initiatives, such as the UK Biobank, have successfully used wearable technologies for data collection from over 100,000 individuals, thus highlighting the potential of wearable technologies in pharmaceutical research. Considering this, pharmaceutical and biotech companies are likely to remain a dominant end user in this market .

“Asia Pacific to witness highest growth rate during forecast period”

The Asia Pacific (APAC) region is experiencing the highest growth rate in the wearables in pharma & biotech market. This growth can be attributed to several factors, including improvements in digital health infrastructure, a rise in clinical research activities, and a significant number of underserved patients. According to the WHO, the combined Western Pacific and Southeast Asia regions contribute a large share to the world’s disease burden. It has been mentioned by the International Telecommunication Union that the penetration of the Internet in the APAC region has surpassed 66% to 70% in recent years. Additionally, it has been observed that countries like China and India are emerging as hubs for clinical trials, with thousands of trials already conducted in these regions. Technology is being adopted to enhance the efficiency of these trials. In September 2024, Biobeat announced its expansion into Argentina and Chile through a partnership with Infinity Pharma.

The breakdown of primary participants is as given below:

• By Company Type – Tier 1: 60%, Tier 2: 30%, and Tier 3: 10%
• By Designation – C-level: 30%, Director-level: 50%, and Others: 20%
• By Region – North America: 45%, Europe: 20%, Asia Pacific: 25%, Rest of the World: 10%.

Abbott (US), Dexcom, Inc. (US), and Masimo (US) are some of the key players in the wearables in pharma & biotech market.

The study includes an in-depth competitive analysis of these key players in the wearables in pharma & biotech market, with their company profiles, recent developments, and key market strategies.

Research Coverage

This research report categorizes the wearables in pharma & biotech market by Product (Smartwatches, Fitness Bands, Smart Rings, Continuous Glucose Monitors (CGM), Patches, Wearable Injectors, Others), Therapeutic Area (cardiovascular (atherosclerotic cardiovascular disease (ASCVD) / secondary prevention, heart failure (HFREF and HFPEF), hypertension, atrial fibrillation (AF) / stroke prevention, pulmonary hypertension, structural heart disease / interventional cardiology), oncology (solid tumors, hematologic malignancies), diabetes, mental health & behavioral health, respiratory disorders, lifestyle & wellness improvement, neurology, musculoskeletal disorders / pain management, women’s health & reproductive health, other diseases), Application (drug discovery, clinical trials (phase ii, phase iii, phase iv), medication adherence & behavioral support, chronic disease monitoring, personalized & preventive digital therapeutics), end user (pharmaceutical & biotech companies, healthcare providers & clinicians, other end users), and region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the wearables in pharma & biotech market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; contracts, partnerships, agreements, new product & service launches, mergers & acquisitions, and recent developments associated with the wearables in pharma & biotech market. Competitive analysis of upcoming startups in the market ecosystem is covered in this report.

Reasons to Buy this Report

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the wearables in pharma & biotech market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.

The report provides insights on the following pointers:

• Analysis of key drivers (Shift toward value-based and patient-centric healthcare models, Rising prevalence of chronic diseases requiring continuous patient monitoring, Rapid digitalization of healthcare and expansion of telehealth services) restraints (High implementation and integration costs for healthcare providers, Data privacy and cybersecurity concerns) opportunities (Expansion of remote patient monitoring and home-based care models, Integration of advanced analytics and personalized healthcare) and challenges (Interoperability limitations with existing healthcare IT systems, Low patient adoption and digital literacy barriers) influencing the growth of the wearables in pharma & biotech market
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the wearables in pharma & biotech market
• Market Development: Comprehensive information about lucrative markets; the report analyses the wearables in pharma & biotech market across varied regions.
• Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the wearables in pharma & biotech market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players like BD (US), Abbott (US), Masimo (US), DexCom, Inc. (US), Medtronic (Ireland), among others, in the wearables in pharma & biotech market.

Table of Contents

1 INTRODUCTION 37
1.1 STUDY OBJECTIVES 37
1.2 MARKET DEFINITION 37
1.3 STUDY SCOPE 38
1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE 38
1.3.2 INCLUSIONS AND EXCLUSIONS 39
1.3.3 YEARS CONSIDERED 40
1.4 CURRENCY CONSIDERED 41
1.5 UNIT CONSIDERED 41
1.6 STAKEHOLDERS 41
2 EXECUTIVE SUMMARY 43
2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS 43
2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS 44
2.3 DISRUPTIVE TRENDS SHAPING WEARABLES IN PHARMA & BIOTECH MARKET 45
2.4 HIGH-GROWTH SEGMENTS 46
2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST 47
3 PREMIUM INSIGHTS 48
3.1 ATTRACTIVE OPPORTUNITIES FOR WEARABLES IN PHARMA & BIOTECH MARKET 48
3.2 NORTH AMERICA WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER AND COUNTRY 49
3.3 WEARABLES IN PHARMA & BIOTECH MARKET, BY COUNTRY 50
4 MARKET OVERVIEW 51
4.1 INTRODUCTION 51
4.2 MARKET DYNAMICS 51
4.2.1 DRIVERS 52
4.2.1.1 Shift toward value-based and patient-centric healthcare models 52
4.2.1.2 Prevalence of chronic diseases requiring continuous patient monitoring 52
4.2.1.3 Rapid digitalization of healthcare and expansion of telehealth services 53
4.2.2 RESTRAINTS 53
4.2.2.1 High implementation and integration costs 53
4.2.2.2 Data privacy and cybersecurity concerns 54
4.2.3 OPPORTUNITIES 54
4.2.3.1 Expansion of remote patient monitoring and home-based care models 54
4.2.3.2 Integration of advanced analytics and personalized healthcare 55
4.2.4 CHALLENGES 55
4.2.4.1 Limited interoperability with existing healthcare IT systems 55
4.2.4.2 Low patient adoption and digital literacy barriers 56
4.3 UNMET NEEDS AND WHITE SPACES 56
4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES 57
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 57
5 INDUSTRY TRENDS 59
5.1 PORTER’S FIVE FORCES ANALYSIS 59
5.1.1 BARGAINING POWER OF SUPPLIERS (MODERATE) 60
5.1.2 BARGAINING POWER OF BUYERS (MODERATE TO HIGH) 60
5.1.3 THREAT OF SUBSTITUTES (LOW TO MODERATE) 60
5.1.4 THREAT OF NEW ENTRANTS (MODERATE) 61
5.1.5 INTENSITY OF COMPETITIVE RIVALRY (HIGH) 61
5.2 MACROECONOMIC INDICATORS 61
5.2.1 GDP TRENDS AND FORECAST 61
5.2.2 TRENDS IN GLOBAL HEALTHCARE IT INDUSTRY 62
5.3 SUPPLY CHAIN ANALYSIS 62
5.4 ECOSYSTEM ANALYSIS 63
5.5 PRICING ANALYSIS 65
5.5.1 INDICATIVE PRICING ANALYSIS OF KEY PLAYERS, BY PRODUCT, 2025 65
5.5.2 INDICATIVE PRICING ANALYSIS, BY REGION, 2025 66
5.6 TRADE ANALYSIS 66
5.6.1 IMPORT DATA (HS CODE 9018) 67
5.6.2 EXPORT DATA (HS CODE 9018) 68
5.7 KEY CONFERENCES AND EVENTS, 2026–2027 68
5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 69
5.9 INVESTMENT AND FUNDING SCENARIO 70
5.10 CASE STUDY ANALYSIS 71
5.11 IMPACT OF 2025 US TARIFF 73
5.11.1 KEY TARIFF RATES 73
5.11.2 PRICE IMPACT ANALYSIS 74
5.11.3 IMPACT ON COUNTRIES/REGIONS 74
5.11.3.1 US 74
5.11.3.2 Europe 75
5.11.3.3 Asia Pacific 76
5.11.4 IMPACT ON END-USE INDUSTRIES 76
5.11.4.1 Pharmaceutical & biotech companies 76
5.11.4.2 Healthcare providers & clinicians 76
5.11.4.3 Other end users 77

6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 78
6.1 KEY TECHNOLOGIES 78
6.1.1 ADVANCED BIOSENSING AND MULTI-PARAMETER WEARABLES 78
6.1.2 AI-DRIVEN ANALYTICS AND CLINICAL INTELLIGENCE 78
6.2 COMPLEMENTARY TECHNOLOGIES 79
6.2.1 MOBILE HEALTH AND REMOTE PATIENT MONITORING 79
6.2.2 ANALYTICS AND POPULATION-LEVEL HEALTH DATA INTEGRATION 79
6.3 ADJACENT TECHNOLOGIES 79
6.3.1 INTERNET OF MEDICAL THINGS AND CONNECTED DEVICES 80
6.3.2 CLOUD AND EDGE COMPUTING 80
6.4 TECHNOLOGY/PRODUCT ROADMAP 80
6.5 PATENT ANALYSIS 81
6.5.1 PATENT PUBLICATION TRENDS 81
6.5.2 JURISDICTION AND TOP APPLICANT ANALYSIS 82
6.6 FUTURE APPLICATIONS 85
6.6.1 AI-DRIVEN PREDICTIVE MONITORING AND CLINICAL DECISION SUPPORT 85
6.6.2 CLOSED-LOOP THERAPEUTIC AND DRUG DELIVERY SYSTEMS 85
6.6.3 DECENTRALIZED AND HYBRID CLINICAL TRIAL ENABLEMENT 85
6.6.4 CONTINUOUS DISEASE MANAGEMENT AND PREVENTIVE HEALTHCARE 85
6.6.5 ADVANCED BIOSENSING AND NON-INVASIVE DIAGNOSTICS 86
6.6.6 INTEGRATION WITH DIGITAL THERAPEUTICS AND PERSONALIZED MEDICINE 86
6.7 IMPACT OF AI/GEN AI 86
6.7.1 MARKET POTENTIAL OF AI/GEN AI 87
6.7.2 CASE STUDIES RELATED TO AI/GEN AI IMPLEMENTATION 88
6.7.2.1 AI-driven continuous glucose monitoring and diabetes management at Dexcom 88
6.7.3 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS 89
6.7.3.1 Wearable data analytics and AI-driven monitoring platforms 89
6.7.3.2 Digital health platforms, integration, and regulatory infrastructure 89
6.7.3.3 Clinical care, remote monitoring, and personalized therapeutics 90
6.7.4 USER READINESS AND IMPACT ASSESSMENT 90
6.7.4.1 User readiness 90
6.7.4.1.1 User A: Hospitals, clinics, and long-term care providers 90
6.7.4.1.2 User B: Pharma and biotech companies 90
6.7.4.2 Impact assessment 91
6.7.4.2.1 User A: Hospitals, clinics, and long-term care providers 91
6.7.4.2.1.1 Implementation 91
6.7.4.2.1.2 Impact 91
6.7.4.2.2 User B: Pharma and biotech companies 91
6.7.4.2.2.1 Implementation 91
6.7.4.2.2.2 Impact 91
7 REGULATORY LANDSCAPE 92
7.1 REGIONAL REGULATIONS AND COMPLIANCE 92
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 93
7.1.2 INDUSTRY STANDARDS 95
8 CUSTOMER LANDSCAPE AND BUYER BEHAVIOR 96
8.1 DECISION-MAKING PROCESS 96
8.2 KEY STAKEHOLDERS IN BUYING PROCESS AND THEIR EVALUATION CRITERIA 96
8.2.1 KEY STAKEHOLDERS INVOLVED IN BUYING PROCESS 96
8.2.2 BUYING CRITERIA 97
8.3 ADOPTION BARRIERS AND INTERNAL CHALLENGES 98
8.4 UNMET NEEDS FROM END-USE INDUSTRIES 99
8.4.1 UNMET NEEDS 99
8.4.2 END-USER EXPECTATIONS 100
8.5 MARKET PROFITABILITY 100
9 WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT 101
9.1 INTRODUCTION 102
9.2 SMARTWATCHES 103
9.2.1 EXPANDING ROLE IN DIGITAL CLINICAL TRIALS AND REMOTE MONITORING 103
9.3 FITNESS BANDS 104
9.3.1 EMPHASIS ON REAL-WORLD EVIDENCE AND
PATIENT-CENTRIC TRIAL DESIGNS 104
9.4 SMART RINGS 105
9.4.1 EMERGING CLINICAL-GRADE WEARABLES ENABLING EARLY
DISEASE DETECTION AND CONTINUOUS MONITORING 105
9.5 CONTINUOUS GLUCOSE MONITORS 106
9.5.1 TRANSFORMING METABOLIC RESEARCH THROUGH REAL-TIME,
HIGH-FREQUENCY DATA 106
9.6 PATCHES 107
9.6.1 CONTINUOUS, CLINICAL-GRADE MONITORING DRIVING ADOPTION IN DECENTRALIZED TRIALS 107
9.7 WEARABLE INJECTORS 109
9.7.1 GROWING DEMAND FOR SELF-ADMINISTRATION OF BIOLOGICS IN
CHRONIC DISEASE MANAGEMENT 109
9.8 OTHER PRODUCTS 110
10 WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA 111
10.1 INTRODUCTION 112
10.2 CARDIOVASCULAR 112
10.2.1 ATHEROSCLEROTIC CARDIOVASCULAR DISEASES/SECONDARY PREVENTION 114
10.2.1.1 Focus on improving endpoint capture and long-term outcomes monitoring 114
10.2.2 HEART FAILURE 115
10.2.2.1 Continuous physiologic monitoring and AI-enabled decompensation prediction 115
10.2.3 HYPERTENSION 116
10.2.3.1 Cuffless monitoring and AI-driven adherence management enabling precision blood pressure control 116
10.2.4 ATRIAL FIBRILLATION/STROKE PREVENTION 118
10.2.4.1 Rapid expansion of AI-powered arrhythmia detection algorithms and regulatory-cleared wearable ECG technologies 118
10.2.5 PULMONARY HYPERTENSION 119
10.2.5.1 Growing use of wearable-enabled remote monitoring and AI analytics to generate objective, real-world functional endpoints 119
10.2.6 STRUCTURAL HEART DISEASES/INTERVENTIONAL CARDIOLOGY 121
10.2.6.1 Wearable-enabled remote recovery monitoring and procedural optimization supporting precision structural heart care 121
10.3 ONCOLOGY 122
10.3.1 SOLID TUMORS 123
10.3.1.1 BREAST CANCER 125
10.3.1.1.1 Continuous wearable-based survivorship monitoring and decentralized oncology trials driving personalized long-term care models 125
10.3.1.2 LUNG CANCER 126
10.3.1.2.1 Constant respiratory monitoring and decentralized trial adoption 126
10.3.1.3 PROSTATE CANCER 127
10.3.1.3.1 Expansion of decentralized oncology trials and long-term survivorship management 127
10.3.1.4 COLORECTAL CANCER 128
10.3.1.4.1 Increasing adoption of decentralized oncology trials and remote post-surgical monitoring 128
10.3.1.5 BRAIN TUMOR 129
10.3.1.5.1 Remote neurologic surveillance and functional recovery tracking accelerating personalized care 129
10.3.1.6 OTHER SOLID TUMORS 130
10.3.2 HEMATOLOGIC MALIGNANCIES 130
10.3.2.1 LEUKEMIA 132
10.3.2.1.1 Wearable-enabled infection surveillance and treatment resilience monitoring transforming outpatient care 132
10.3.2.2 LYMPHOMA 133
10.3.2.2.1 Shift toward outpatient infusion centers, home-based recovery, and decentralized clinical trials 133
10.3.2.3 MULTIPLE MYELOMA 134
10.3.2.3.1 Real-time toxicity and mobility tracking using wearables in long-term management 134
10.3.2.4 OTHER HEMATOLOGIC MALIGNANCIES 135

10.3.3 DIABETES 136
10.3.3.1 Critical need for long-term, real-world metabolic monitoring 136
10.3.4 MENTAL HEALTH & BEHAVIORAL HEALTH 138
10.3.4.1 Rising global burden of psychiatric disorders 138
10.3.5 RESPIRATORY DISORDERS 139
10.3.5.1 Early exacerbation detection through continuous monitoring reduces hospitalization 139
10.3.6 LIFESTYLE & WELLNESS IMPROVEMENT 140
10.3.6.1 Continuous tracking for lifestyle optimization and preventive health risk management 140
10.3.7 NEUROLOGY 142
10.3.7.1 Wearable-based monitoring of neurological function and digital clinical endpoints in CNS disorders 142
10.3.8 MUSCULOSKELETAL DISORDERS/PAIN MANAGEMENT 144
10.3.8.1 Wearable-guided functional movement and chronic pain monitoring in musculoskeletal disorders 144
10.3.9 WOMEN’S HEALTH & REPRODUCTIVE HEALTH 145
10.3.9.1 Continuous physiological and reproductive cycle using wearables 145
10.3.10 OTHER DISEASES 146
11 WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION 148
11.1 INTRODUCTION 149
11.2 DRUG DISCOVERY 149
11.2.1 RECENT ADVANCES PROMOTE DISCOVERY OF DRUGS THROUGH WEARABLES IN PHARMA & BIOTECH 149
11.3 CLINICAL TRIALS 151
11.3.1 PHASE II 152
11.3.1.1 AI-enabled remote monitoring and adaptive trial designs accelerate adoption 152
11.3.2 PHASE III 153
11.3.2.1 Rapid expansion of decentralized and hybrid global trial models propels growth 153
11.3.3 PHASE IV 155
11.3.3.1 Ability to improve patient engagement and retention in long-duration studies drives market 155
11.4 MEDICATION ADHERENCE & BEHAVIORAL SUPPORT 156
11.4.1 CONNECTED REMINDERS, PASSIVE MONITORING, AND PERSONALIZED NUDGES BOOST ADOPTION 156
11.5 CHRONIC DISEASE MONITORING 158
11.5.1 CONTINUOUS PHYSIOLOGICAL TRACKING AND PROACTIVE INTERVENTION CAPABILITIES INCREASE ADOPTION 158
11.6 PERSONALIZED & PREVENTIVE DIGITAL THERAPEUTICS 159
11.6.1 BIOMETRIC SENSING AND AI-DRIVEN COACHING RAISE DEMAND FOR WEARABLES 159

12 WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER 161
12.1 INTRODUCTION 162
12.2 PHARMACEUTICAL & BIOTECH COMPANIES 162
12.2.1 CLINICAL DIGITIZATION, REAL-WORLD EVIDENCE GENERATION, AND CONNECTED THERAPY MODELS DRIVE MARKET 162
12.3 HEALTHCARE PROVIDERS & CLINICIANS 163
12.3.1 REMOTE PATIENT MONITORING, PREVENTIVE CARE, AND DATA-DRIVEN CLINICAL DECISION SUPPORT BOOST GROWTH 163
12.4 CONTRACT RESEARCH ORGANIZATIONS 165
12.4.1 DECENTRALIZED TRIALS, WEARABLE DATA INTEGRATION, AND FASTER CLINICAL EXECUTION RAISE DEMAND 165
12.5 OTHER END USERS 166
13 WEARABLES IN PHARMA & BIOTECH MARKET, BY REGION 168
13.1 INTRODUCTION 169
13.2 NORTH AMERICA 169
13.2.1 US 175
13.2.1.1 High concentration of clinical research activity, clinical trial inefficiencies, and cost pressures to drive market 175
13.2.2 CANADA 180
13.2.2.1 Clinical research participation, public health burden, and digital health adoption to drive market 180
13.3 EUROPE 184
13.3.1 GERMANY 189
13.3.1.1 Expanding clinical trial activity and regulatory leadership to drive market 189
13.3.2 FRANCE 193
13.3.2.1 Regulatory-first approach to healthcare and clinical innovation to drive market 193
13.3.3 UK 197
13.3.3.1 Real-world data integration and decentralized trial innovation to drive market 197
13.3.4 ITALY 201
13.3.4.1 Evolving clinical trial landscape and regulatory decentralization to drive market 201
13.3.5 SPAIN 205
13.3.5.1 Increasing investment in digital health infrastructure to drive market 205
13.3.6 REST OF EUROPE 209
13.4 ASIA PACIFIC 213
13.4.1 CHINA 219
13.4.1.1 Clinical trial expansion and real-world data integration to drive market 219
13.4.2 JAPAN 223
13.4.2.1 Late-stage trial leadership and regulatory precision to drive market 223
13.4.3 INDIA 227
13.4.3.1 High-volume Phase III trial ecosystem and ABDM-driven digital health integration to drive market 227
13.4.4 AUSTRALIA 232
13.4.4.1 Early-phase trial leadership and remote care needs to drive market 232
13.4.5 SOUTH KOREA 236
13.4.5.1 Integrated clinical trial ecosystem and national health data infrastructure to drive market 236
13.4.6 REST OF ASIA PACIFIC 240
13.5 LATIN AMERICA 244
13.5.1 BRAZIL 249
13.5.1.1 Clinical trial leadership and high diabetes burden to drive market 249
13.5.2 MEXICO 253
13.5.2.1 Regulatory reforms and Phase III trial expansion to drive market 253
13.5.3 REST OF LATIN AMERICA 257
13.6 MIDDLE EAST & AFRICA 261
13.6.1 GCC 265
13.6.2 SAUDI ARABIA 269
13.6.2.1 Vision 2030–led digital health transformation to drive market 269
13.6.3 UAE 273
13.6.3.1 Digital health strategy, clinical trial expansion, and high healthcare investment to drive market 273
13.6.4 REST OF GCC 277
13.6.5 SOUTH AFRICA 281
13.6.5.1 Clinical trial leadership and decentralized care models to drive market 281
13.6.6 REST OF MIDDLE EAST & AFRICA 285
14 COMPETITIVE LANDSCAPE 290
14.1 OVERVIEW 290
14.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2023–2026 290
14.3 REVENUE ANALYSIS, 2021–2025 292
14.4 MARKET SHARE ANALYSIS, 2025 292
14.5 BRAND/PRODUCT COMPARISON 295
14.6 COMPANY VALUATION AND FINANCIAL METRICS 296
14.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 297
14.7.1 STARS 297
14.7.2 EMERGING LEADERS 297
14.7.3 PERVASIVE PLAYERS 297
14.7.4 PARTICIPANTS 297
14.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 299
14.7.5.1 Company footprint 299
14.7.5.2 Region footprint 300
14.7.5.3 Product footprint 301
14.7.5.4 Therapeutic area footprint 302
14.7.5.5 Application footprint 303
14.7.5.6 End user footprint 304
14.8 COMPANY EVALUATION MATRIX: START-UPS/SMES, 2025 305
14.8.1 PROGRESSIVE COMPANIES 305
14.8.2 RESPONSIVE COMPANIES 305
14.8.3 DYNAMIC COMPANIES 305
14.8.4 STARTING BLOCKS 305
14.8.5 COMPETITIVE BENCHMARKING: START-UPS/SMES, 2025 307
14.8.5.1 List of start-ups/SMEs 307
14.8.5.2 Competitive benchmarking of start-ups/SMEs 307
14.9 COMPETITIVE SCENARIO 308
14.9.1 PRODUCT LAUNCHES AND APPROVALS 308
14.9.2 DEALS 309
14.9.3 OTHER DEVELOPMENTS 309
15 COMPANY PROFILES 310
15.1 KEY PLAYERS 310
15.1.1 DEXCOM, INC. 310
15.1.1.1 Business overview 310
15.1.1.2 Products offered 311
15.1.1.3 Recent developments 312
15.1.1.3.1 Product launches and approvals 312
15.1.1.3.2 Deals 312
15.1.1.4 MnM view 313
15.1.1.4.1 Right to win 313
15.1.1.4.2 Strategic choices 313
15.1.1.4.3 Weaknesses and competitive threats 314
15.1.2 ABBOTT 315
15.1.2.1 Business overview 315
15.1.2.2 Products offered 316
15.1.2.3 Recent developments 317
15.1.2.3.1 Product launches and approvals 317
15.1.2.3.2 Deals 318
15.1.2.3.3 Other developments 318
15.1.2.4 MnM view 318
15.1.2.4.1 Right to win 318
15.1.2.4.2 Strategic choices 319
15.1.2.4.3 Weaknesses and competitive threats 319

15.1.3 MASIMO 320
15.1.3.1 Business overview 320
15.1.3.2 Products offered 321
15.1.3.3 Recent developments 322
15.1.3.3.1 Product launches and approvals 322
15.1.3.3.2 Deals 323
15.1.3.4 MnM view 324
15.1.3.4.1 Right to win 324
15.1.3.4.2 Strategic choices 324
15.1.3.4.3 Weaknesses and competitive threats 324
15.1.4 BD 325
15.1.4.1 Business overview 325
15.1.4.2 Products offered 326
15.1.4.3 Recent developments 327
15.1.4.3.1 Product launches and approvals 327
15.1.4.3.2 Deals 327
15.1.4.4 MnM view 328
15.1.4.4.1 Right to win 328
15.1.4.4.2 Strategic choices 328
15.1.4.4.3 Weaknesses and competitive threats 328
15.1.5 APPLE INC. 329
15.1.5.1 Business overview 329
15.1.5.2 Products offered 330
15.1.5.3 Recent developments 331
15.1.5.3.1 Product launches and approvals 331
15.1.5.3.2 Deals 331
15.1.5.4 MnM view 332
15.1.5.4.1 Right to win 332
15.1.5.4.2 Strategic choices 332
15.1.5.4.3 Weaknesses and competitive threats 332
15.1.6 BOSTON SCIENTIFIC CORPORATION 333
15.1.6.1 Business overview 333
15.1.6.2 Products offered 334
15.1.6.3 Recent developments 335
15.1.6.3.1 Deals 335
15.1.7 IRHYTHM TECHNOLOGIES, INC. 336
15.1.7.1 Business overview 336
15.1.7.2 Products offered 337
15.1.7.3 Recent developments 338
15.1.7.3.1 Product launches and approvals 338
15.1.7.3.2 Deals 338

15.1.8 KONINKLIJKE PHILIPS N.V. 339
15.1.8.1 Business overview 339
15.1.8.2 Products offered 340
15.1.8.3 Recent developments 341
15.1.8.3.1 Product launches and approvals 341
15.1.8.3.2 Deals 341
15.1.8.3.3 Other developments 342
15.1.9 MEDTRONIC 343
15.1.9.1 Business overview 343
15.1.9.2 Products offered 344
15.1.9.3 Recent developments 345
15.1.9.3.1 Deals 345
15.1.10 BIOINTELLISENSE, INC. 346
15.1.10.1 Business overview 346
15.1.10.2 Products offered 347
15.1.10.3 Recent developments 347
15.1.10.3.1 Product launches and approvals 347
15.1.10.3.2 Deals 348
15.1.11 F. HOFFMANN-LA ROCHE LTD 349
15.1.11.1 Business overview 349
15.1.11.2 Products offered 350
15.1.11.3 Recent developments 351
15.1.11.3.1 Product launches and approvals 351
15.1.12 GE HEALTHCARE 352
15.1.12.1 Business overview 352
15.1.12.2 Products offered 353
15.1.12.3 Recent developments 354
15.1.12.3.1 Product launches and approvals 354
15.1.12.3.2 Deals 354
15.1.13 BIOBEAT 355
15.1.13.1 Business overview 355
15.1.13.2 Products offered 355
15.1.13.3 Recent developments 356
15.1.13.3.1 Product launches and approvals 356
15.1.13.3.2 Deals 357
15.1.13.3.3 Other developments 357
15.1.14 EMPATICA INC. 358
15.1.14.1 Business overview 358
15.1.14.2 Products offered 359
15.1.14.3 Recent developments 359
15.1.14.3.1 Product launches and approvals 359
15.1.14.3.2 Deals 360
15.1.15 VITALCONNECT 361
15.1.15.1 Business overview 361
15.1.15.2 Products offered 361
15.1.15.3 Recent developments 362
15.1.15.3.1 Deals 362
15.1.15.3.2 Other developments 362
15.1.16 AMETRIS, LLC 363
15.1.16.1 Business overview 363
15.1.16.2 Products offered 363
15.1.16.3 Recent developments 364
15.1.16.3.1 Deals 364
15.1.17 ALIVECOR, INC. 366
15.1.17.1 Business overview 366
15.1.17.2 Products offered 366
15.1.17.3 Recent developments 367
15.1.17.3.1 Product launches and approvals 367
15.1.17.3.2 Deals 368
15.1.18 WITHINGS 369
15.1.18.1 Business overview 369
15.1.18.2 Products offered 370
15.1.18.3 Recent developments 370
15.1.18.3.1 Product launches and approvals 370
15.1.18.3.2 Deals 371
15.1.19 VIVALNK, INC. 372
15.1.19.1 Business overview 372
15.1.19.2 Products offered 372
15.1.19.3 Recent developments 373
15.1.19.3.1 Product launches and approvals 373
15.1.20 MEDIBIOSENSE 374
15.1.20.1 Business overview 374
15.1.20.2 Products offered 374
15.1.20.3 Recent developments 375
15.1.20.3.1 Product launches and approvals 375
15.2 OTHER PLAYERS 376
15.2.1 SIBEL HEALTH, INC. 376
15.2.2 BYTEFLIES 376
15.2.3 STRADOS LABS 377
15.2.4 ONERA TECHNOLOGIES B.V. 377
15.2.5 EPICORE BIOSYSTEMS, INC. 378

16 RESEARCH METHODOLOGY 379
16.1 RESEARCH APPROACH 379
16.1.1 SECONDARY RESEARCH 380
16.1.1.1 Key data from secondary sources 381
16.1.2 PRIMARY RESEARCH 381
16.1.2.1 Primary sources 382
16.1.2.2 Key data from primary sources 383
16.1.2.3 Breakdown of primary interviews 383
16.1.2.4 Insights from primary experts 384
16.2 RESEARCH METHODOLOGY DESIGN 384
16.3 MARKET SIZE ESTIMATION 385
16.4 DATA TRIANGULATION 390
16.5 RESEARCH ASSUMPTIONS 391
16.6 RESEARCH LIMITATIONS 391
16.6.1 METHODOLOGY-RELATED 391
16.6.2 SCOPE-RELATED 391
16.7 RISK ASSESSMENT 392
17 APPENDIX 393
17.1 DISCUSSION GUIDE 393
17.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 397
17.3 CUSTOMIZATION OPTIONS 399
17.4 RELATED REPORTS 399
17.5 AUTHOR DETAILS 400

LIST OF TABLES

TABLE 1 EXCHANGE RATES FOR CURRENCY CONVERSION 41
TABLE 2 IMPACT OF PORTER’S FIVE FORCES 60
TABLE 3 ROLE OF COMPANIES IN ECOSYSTEM 64
TABLE 4 INDICATIVE PRICES OF WEARABLES IN PHARMA & BIOTECH MARKET,
BY PRODUCT, 2025 65
TABLE 5 INDICATIVE PRICES OF WEARABLES IN PHARMA & BIOTECH MARKET,
BY REGION, 2025 66
TABLE 6 IMPORT DATA FOR HS CODE 9018-COMPLIANT PRODUCTS, BY COUNTRY,
2021–2024 (USD MILLION) 67
TABLE 7 EXPORT DATA FOR HS CODE 9018-COMPLIANT PRODUCTS, BY COUNTRY,
2021–2024 (USD MILLION) 68
TABLE 8 KEY CONFERENCES AND EVENTS, 2026–2027 69
TABLE 9 CASE 1: CLINICAL GRADE WEARABLE VITAL SIGNS MONITORING IN NEONATAL & MATERNAL TRIALS 71
TABLE 10 CASE 2: MULTI LEAD WEARABLE ECG MONITORING FOR CARDIOLOGY TRIALS 71
TABLE 11 CASE 3: CONTINUOUS RESPIRATORY MONITORING IN CHRONIC LUNG DISEASE 72
TABLE 12 US-ADJUSTED RECIPROCAL TARIFF RATES 73
TABLE 13 JURISDICTION ANALYSIS OF TOP APPLICANT COUNTRIES 82
TABLE 14 LIST OF PATENTS/PATENT APPLICATIONS 84
TABLE 15 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 93
TABLE 16 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 93
TABLE 17 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 94
TABLE 18 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 94
TABLE 19 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 95
TABLE 20 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER (%) 97
TABLE 21 KEY BUYING CRITERIA, BY END USER 98
TABLE 22 UNMET NEEDS IN WEARABLES IN PHARMA & BIOTECH MARKET 99
TABLE 23 END-USER EXPECTATIONS IN WEARABLES IN PHARMA & BIOTECH MARKET 100
TABLE 24 WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 102
TABLE 25 WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT,
2024–2031 (THOUSAND UNITS) 102
TABLE 26 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR SMARTWATCHES 103
TABLE 27 WEARABLES IN PHARMA & BIOTECH MARKET FOR SMARTWATCHES, BY REGION, 2024–2031 (USD MILLION) 103
TABLE 28 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR FITNESS BANDS 104
TABLE 29 WEARABLES IN PHARMA & BIOTECH MARKET FOR FITNESS BANDS, BY REGION, 2024–2031 (USD MILLION) 105
TABLE 30 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR SMART RINGS 105
TABLE 31 WEARABLES IN PHARMA & BIOTECH MARKET FOR SMART RINGS,
BY REGION, 2024–2031 (USD MILLION) 106
TABLE 32 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR CONTINUOUS GLUCOSE MONITORS 107
TABLE 33 WEARABLES IN PHARMA & BIOTECH MARKET FOR CONTINUOUS GLUCOSE MONITORS, BY REGION, 2024–2031 (USD MILLION) 107
TABLE 34 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR PATCHES 108
TABLE 35 WEARABLES IN PHARMA & BIOTECH MARKET FOR PATCHES, BY REGION,
2024–2031 (USD MILLION) 108
TABLE 36 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR WEARABLE INJECTORS 109
TABLE 37 WEARABLES IN PHARMA & BIOTECH MARKET FOR WEARABLE INJECTORS,
BY REGION, 2024–2031 (USD MILLION) 109
TABLE 38 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET
FOR OTHER PRODUCTS 110
TABLE 39 WEARABLES IN PHARMA & BIOTECH MARKET FOR OTHER PRODUCTS, BY REGION, 2024–2031 (USD MILLION) 110
TABLE 40 WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 112
TABLE 41 WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR,
BY TYPE, 2024–2031 (USD MILLION) 113
TABLE 42 WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR,
BY REGION, 2024–2031 (USD MILLION) 113
TABLE 43 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR ATHEROSCLEROTIC CARDIOVASCULAR DISEASES/SECONDARY PREVENTION 115
TABLE 44 WEARABLES IN PHARMA & BIOTECH MARKET FOR ATHEROSCLEROTIC CARDIOVASCULAR DISEASES/SECONDARY PREVENTION, BY REGION,
2024–2031 (USD MILLION) 115
TABLE 45 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR HEART FAILURE 116
TABLE 46 WEARABLES IN PHARMA & BIOTECH MARKET FOR HEART FAILURE,
BY REGION, 2024–2031 (USD MILLION) 116
TABLE 47 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR HYPERTENSION 117
TABLE 48 WEARABLES IN PHARMA & BIOTECH MARKET FOR HYPERTENSION,
BY REGION, 2024–2031 (USD MILLION) 117
TABLE 49 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR ATRIAL FIBRILLATION/STROKE PREVENTION 118
TABLE 50 WEARABLES IN PHARMA & BIOTECH MARKET FOR ATRIAL FIBRILLATION/
STROKE PREVENTION, BY REGION, 2024–2031 (USD MILLION) 119
TABLE 51 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR
PULMONARY HYPERTENSION 120
TABLE 52 WEARABLES IN PHARMA & BIOTECH MARKET FOR PULMONARY HYPERTENSION, BY REGION, 2024–2031 (USD MILLION) 120
TABLE 53 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR STRUCTURAL HEART DISEASES/INTERVENTIONAL CARDIOLOGY 121
TABLE 54 WEARABLES IN PHARMA & BIOTECH MARKET FOR STRUCTURAL HEART DISEASES/INTERVENTIONAL CARDIOLOGY, BY REGION,
2024–2031 (USD MILLION) 122
TABLE 55 WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY,
BY TYPE, 2024–2031 (USD MILLION) 122
TABLE 56 WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY, BY REGION,
2024–2031 (USD MILLION) 123
TABLE 57 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS 124
TABLE 58 WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION) 124
TABLE 59 WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY REGION, 2024–2031 (USD MILLION) 124
TABLE 60 WEARABLES IN PHARMA & BIOTECH MARKET FOR BREAST CANCER, BY REGION, 2024–2031 (USD MILLION) 125
TABLE 61 WEARABLES IN PHARMA & BIOTECH MARKET FOR LUNG CANCER, BY REGION, 2024–2031 (USD MILLION) 126
TABLE 62 WEARABLES IN PHARMA & BIOTECH MARKET FOR PROSTATE CANCER, BY REGION, 2024–2031 (USD MILLION) 127
TABLE 63 WEARABLES IN PHARMA & BIOTECH MARKET FOR COLORECTAL CANCER,
BY REGION, 2024–2031 (USD MILLION) 128
TABLE 64 WEARABLES IN PHARMA & BIOTECH MARKET FOR BRAIN TUMOR, BY REGION, 2024–2031 (USD MILLION) 129
TABLE 65 WEARABLES IN PHARMA & BIOTECH MARKET FOR OTHER SOLID TUMORS,
BY REGION, 2024–2031 (USD MILLION) 130
TABLE 66 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR
HEMATOLOGIC MALIGNANCIES 131
TABLE 67 WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC
MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 131
TABLE 68 WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC
MALIGNANCIES, BY REGION, 2024–2031 (USD MILLION) 132
TABLE 69 WEARABLES IN PHARMA & BIOTECH MARKET FOR LEUKEMIA, BY REGION,
2024–2031 (USD MILLION) 133
TABLE 70 WEARABLES IN PHARMA & BIOTECH MARKET FOR LYMPHOMA, BY REGION,
2024–2031 (USD MILLION) 134
TABLE 71 WEARABLES IN PHARMA & BIOTECH MARKET FOR MULTIPLE MYELOMA,
BY REGION, 2024–2031 (USD MILLION) 135
TABLE 72 WEARABLES IN PHARMA & BIOTECH MARKET FOR OTHER HEMATOLOGIC MALIGNANCIES, BY REGION, 2024–2031 (USD MILLION) 136
TABLE 73 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR DIABETES 137
TABLE 74 WEARABLES IN PHARMA & BIOTECH MARKET FOR DIABETES, BY REGION,
2024–2031 (USD MILLION) 137
TABLE 75 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR MENTAL
HEALTH & BEHAVIORAL HEALTH 138
TABLE 76 WEARABLES IN PHARMA & BIOTECH MARKET FOR MENTAL HEALTH & BEHAVIORAL HEALTH, BY REGION, 2024–2031 (USD MILLION) 139
TABLE 77 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR
RESPIRATORY DISORDERS 140
TABLE 78 WEARABLES IN PHARMA & BIOTECH MARKET FOR RESPIRATORY
DISORDERS, BY REGION, 2024–2031 (USD MILLION) 140
TABLE 79 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR LIFESTYLE & WELLNESS IMPROVEMENT 141
TABLE 80 WEARABLES IN PHARMA & BIOTECH MARKET FOR LIFESTYLE & WELLNESS IMPROVEMENT, BY REGION, 2024–2031 (USD MILLION) 142
TABLE 81 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR NEUROLOGY 143
TABLE 82 WEARABLES IN PHARMA & BIOTECH MARKET FOR NEUROLOGY, BY REGION, 2024–2031 (USD MILLION) 143
TABLE 83 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR MUSCULOSKELETAL DISORDERS/PAIN MANAGEMENT 144
TABLE 84 WEARABLES IN PHARMA & BIOTECH MARKET FOR MUSCULOSKELETAL DISORDERS/PAIN MANAGEMENT, BY REGION, 2024–2031 (USD MILLION) 145
TABLE 85 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR WOMEN’S HEALTH & REPRODUCTIVE HEALTH 146
TABLE 86 WEARABLES IN PHARMA & BIOTECH MARKET FOR WOMEN’S HEALTH & REPRODUCTIVE HEALTH, BY REGION, 2024–2031 (USD MILLION) 146
TABLE 87 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET
FOR OTHER DISEASES 147
TABLE 88 WEARABLES IN PHARMA & BIOTECH MARKET FOR OTHER DISEASES,
BY REGION, 2024–2031 (USD MILLION) 147
TABLE 89 WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 149
TABLE 90 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR
DRUG DISCOVERY 150
TABLE 91 WEARABLES IN PHARMA & BIOTECH MARKET FOR DRUG DISCOVERY,
BY REGION, 2024–2031 (USD MILLION) 150
TABLE 92 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS 151
TABLE 93 WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS,
BY TYPE, 2024–2031 (USD MILLION) 151
TABLE 94 WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS,
BY REGION, 2024–2031 (USD MILLION) 152
TABLE 95 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR
PHASE II CLINICAL TRIALS 153
TABLE 96 WEARABLES IN PHARMA & BIOTECH MARKET FOR PHASE II CLINICAL TRIALS,
BY REGION, 2024–2031 (USD MILLION) 153
TABLE 97 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR
PHASE III CLINICAL TRIALS 154
TABLE 98 WEARABLES IN PHARMA & BIOTECH MARKET FOR PHASE III CLINICAL TRIALS,
BY REGION, 2024–2031 (USD MILLION) 154
TABLE 99 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR
PHASE IV CLINICAL TRIALS 156
TABLE 100 WEARABLES IN PHARMA & BIOTECH MARKET FOR PHASE IV CLINICAL TRIALS,
BY REGION, 2024–2031 (USD MILLION) 156
TABLE 101 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR MEDICATION ADHERENCE & BEHAVIORAL SUPPORT 157
TABLE 102 WEARABLES IN PHARMA & BIOTECH MARKET FOR MEDICATION ADHERENCE & BEHAVIORAL SUPPORT, BY REGION, 2024–2031 (USD MILLION) 158
TABLE 103 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR
CHRONIC DISEASE MONITORING 159
TABLE 104 WEARABLES IN PHARMA & BIOTECH MARKET FOR CHRONIC DISEASE MONITORING, BY REGION, 2024–2031 (USD MILLION) 159
TABLE 105 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR
PERSONALIZED & PREVENTIVE DIGITAL THERAPEUTICS 160
TABLE 106 WEARABLES IN PHARMA & BIOTECH MARKET FOR PERSONALIZED & PREVENTIVE DIGITAL THERAPEUTICS, BY REGION, 2024–2031 (USD MILLION) 160
TABLE 107 WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER,
2024–2031 (USD MILLION) 162
TABLE 108 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR PHARMACEUTICAL & BIOTECH COMPANIES 163
TABLE 109 WEARABLES IN PHARMA & BIOTECH MARKET FOR PHARMACEUTICAL &
BIOTECH COMPANIES, BY REGION, 2024–2031 (USD MILLION) 163
TABLE 110 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR
HEALTHCARE PROVIDERS & CLINICIANS 164
TABLE 111 WEARABLES IN PHARMA & BIOTECH MARKET FOR HEALTHCARE PROVIDERS & CLINICIANS, BY REGION, 2024–2031 (USD MILLION) 164
TABLE 112 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR
CONTRACT RESEARCH ORGANIZATIONS 165
TABLE 113 WEARABLES IN PHARMA & BIOTECH MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2024–2031 (USD MILLION) 166
TABLE 114 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET
FOR OTHER END USERS 166
TABLE 115 WEARABLES IN PHARMA & BIOTECH MARKET FOR OTHER END USERS,
BY REGION, 2024–2031 (USD MILLION) 167
TABLE 116 WEARABLES IN PHARMA & BIOTECH MARKET, BY REGION,
2024–2031 (USD MILLION) 169
TABLE 117 NORTH AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 171
TABLE 118 NORTH AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET,
BY PRODUCT, 2024–2031 (USD MILLION) 171
TABLE 119 NORTH AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET,
BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 172
TABLE 120 NORTH AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET
FOR CARDIOVASCULAR, BY TYPE, 2024–2031 (USD MILLION) 172
TABLE 121 NORTH AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET
FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION) 173
TABLE 122 NORTH AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET
FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION) 173
TABLE 123 NORTH AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 173
TABLE 124 NORTH AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET,
BY APPLICATION, 2024–2031 (USD MILLION) 174
TABLE 125 NORTH AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET
FOR CLINICAL TRIALS, BY TYPE, 2024–2031 (USD MILLION) 174
TABLE 126 NORTH AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET,
BY END USER, 2024–2031 (USD MILLION) 174
TABLE 127 US: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 176
TABLE 128 US: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 176
TABLE 129 US: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR,
BY TYPE, 2024–2031 (USD MILLION) 177
TABLE 130 US: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY,
BY TYPE, 2024–2031 (USD MILLION) 177
TABLE 131 US: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS,
BY TYPE, 2024–2031 (USD MILLION) 178
TABLE 132 US: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 178
TABLE 133 US: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 179
TABLE 134 US: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS,
BY TYPE, 2024–2031 (USD MILLION) 179
TABLE 135 US: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER,
2024–2031 (USD MILLION) 179
TABLE 136 CANADA: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 180
TABLE 137 CANADA: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 181
TABLE 138 CANADA: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR,
BY TYPE, 2024–2031 (USD MILLION) 181
TABLE 139 CANADA: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY,
BY TYPE, 2024–2031 (USD MILLION) 182
TABLE 140 CANADA: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS,
BY TYPE, 2024–2031 (USD MILLION) 182
TABLE 141 CANADA: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 182
TABLE 142 CANADA: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 183
TABLE 143 CANADA: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS,
BY TYPE, 2024–2031 (USD MILLION) 183
TABLE 144 CANADA: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER,
2024–2031 (USD MILLION) 183
TABLE 145 EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 184
TABLE 146 EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 185
TABLE 147 EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 185
TABLE 148 EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR,
BY TYPE, 2024–2031 (USD MILLION) 186
TABLE 149 EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY,
BY TYPE, 2024–2031 (USD MILLION) 186
TABLE 150 EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS,
BY TYPE, 2024–2031 (USD MILLION) 187
TABLE 151 EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 187
TABLE 152 EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 188
TABLE 153 EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS,
BY TYPE, 2024–2031 (USD MILLION) 188
TABLE 154 EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER,
2024–2031 (USD MILLION) 188
TABLE 155 GERMANY: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 189
TABLE 156 GERMANY: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 190
TABLE 157 GERMANY: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY TYPE, 2024–2031 (USD MILLION) 190
TABLE 158 GERMANY: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY,
BY TYPE, 2024–2031 (USD MILLION) 191
TABLE 159 GERMANY: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS,
BY TYPE, 2024–2031 (USD MILLION) 191
TABLE 160 GERMANY: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 191
TABLE 161 GERMANY: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 192
TABLE 162 GERMANY: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS,
BY TYPE, 2024–2031 (USD MILLION) 192
TABLE 163 GERMANY: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER,
2024–2031 (USD MILLION) 192
TABLE 164 FRANCE: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 193
TABLE 165 FRANCE: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 194
TABLE 166 FRANCE: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR,
BY TYPE, 2024–2031 (USD MILLION) 194
TABLE 167 FRANCE: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY,
BY TYPE, 2024–2031 (USD MILLION) 195
TABLE 168 FRANCE: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS,
BY TYPE, 2024–2031 (USD MILLION) 195
TABLE 169 FRANCE: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 195
TABLE 170 FRANCE: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 196
TABLE 171 FRANCE: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS,
BY TYPE, 2024–2031 (USD MILLION) 196
TABLE 172 FRANCE: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER,
2024–2031 (USD MILLION) 196
TABLE 173 UK: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 197
TABLE 174 UK: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 198
TABLE 175 UK: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR,
BY TYPE, 2024–2031 (USD MILLION) 198
TABLE 176 UK: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION) 199
TABLE 177 UK: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION) 199
TABLE 178 UK: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 199
TABLE 179 UK: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 200
TABLE 180 UK: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS, BY TYPE, 2024–2031 (USD MILLION) 200
TABLE 181 UK: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER,
2024–2031 (USD MILLION) 200
TABLE 182 ITALY: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 201
TABLE 183 ITALY: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 202
TABLE 184 ITALY: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR,
BY TYPE, 2024–2031 (USD MILLION) 202
TABLE 185 ITALY: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY,
BY TYPE, 2024–2031 (USD MILLION) 203
TABLE 186 ITALY: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS,
BY TYPE, 2024–2031 (USD MILLION) 203
TABLE 187 ITALY: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 203
TABLE 188 ITALY: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 204
TABLE 189 ITALY: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS,
BY TYPE, 2024–2031 (USD MILLION) 204
TABLE 190 ITALY: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER,
2024–2031 (USD MILLION) 204
TABLE 191 SPAIN: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 205
TABLE 192 SPAIN: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 206
TABLE 193 SPAIN: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR,
BY TYPE, 2024–2031 (USD MILLION) 206
TABLE 194 SPAIN: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY,
BY TYPE, 2024–2031 (USD MILLION) 207
TABLE 195 SPAIN: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS,
BY TYPE, 2024–2031 (USD MILLION) 207
TABLE 196 SPAIN: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 207
TABLE 197 SPAIN: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 208
TABLE 198 SPAIN: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS,
BY TYPE, 2024–2031 (USD MILLION) 208
TABLE 199 SPAIN: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER,
2024–2031 (USD MILLION) 208
TABLE 200 REST OF EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 209
TABLE 201 REST OF EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 210
TABLE 202 REST OF EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY TYPE, 2024–2031 (USD MILLION) 210
TABLE 203 REST OF EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION) 211
TABLE 204 REST OF EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION) 211
TABLE 205 REST OF EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 211
TABLE 206 REST OF EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 212
TABLE 207 REST OF EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS, BY TYPE, 2024–2031 (USD MILLION) 212
TABLE 208 REST OF EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET,
BY END USER, 2024–2031 (USD MILLION) 212
TABLE 209 ASIA PACIFIC: WEARABLES IN PHARMA & BIOTECH MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 214
TABLE 210 ASIA PACIFIC: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 215
TABLE 211 ASIA PACIFIC: WEARABLES IN PHARMA & BIOTECH MARKET,
BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 215
TABLE 212 ASIA PACIFIC: WEARABLES IN PHARMA & BIOTECH MARKET
FOR CARDIOVASCULAR, BY TYPE, 2024–2031 (USD MILLION) 216
TABLE 213 ASIA PACIFIC: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY,
BY TYPE, 2024–2031 (USD MILLION) 216
TABLE 214 ASIA PACIFIC: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION) 217
TABLE 215 ASIA PACIFIC: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 217
TABLE 216 ASIA PACIFIC: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 218
TABLE 217 ASIA PACIFIC: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS, BY TYPE, 2024–2031 (USD MILLION) 218
TABLE 218 ASIA PACIFIC: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER,
2024–2031 (USD MILLION) 218
TABLE 219 CHINA: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 219
TABLE 220 CHINA: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 220
TABLE 221 CHINA: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR,
BY TYPE, 2024–2031 (USD MILLION) 220
TABLE 222 CHINA: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY,
BY TYPE, 2024–2031 (USD MILLION) 221
TABLE 223 CHINA: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS,
BY TYPE, 2024–2031 (USD MILLION) 221
TABLE 224 CHINA: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 221
TABLE 225 CHINA: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 222
TABLE 226 CHINA: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS,
BY TYPE, 2024–2031 (USD MILLION) 222
TABLE 227 CHINA: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER,
2024–2031 (USD MILLION) 222
TABLE 228 JAPAN: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 223
TABLE 229 JAPAN: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 224
TABLE 230 JAPAN: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR,
BY TYPE, 2024–2031 (USD MILLION) 224
TABLE 231 JAPAN: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION) 225
TABLE 232 JAPAN: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS,
BY TYPE, 2024–2031 (USD MILLION) 225
TABLE 233 JAPAN: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 225
TABLE 234 JAPAN: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 226
TABLE 235 JAPAN: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS,
BY TYPE, 2024–2031 (USD MILLION) 226
TABLE 236 JAPAN: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER,
2024–2031 (USD MILLION) 226
TABLE 237 INDIA: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 228
TABLE 238 INDIA: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 228
TABLE 239 INDIA: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR,
BY TYPE, 2024–2031 (USD MILLION) 229
TABLE 240 INDIA: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY,
BY TYPE, 2024–2031 (USD MILLION) 229
TABLE 241 INDIA: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS,
BY TYPE, 2024–2031 (USD MILLION) 230
TABLE 242 INDIA: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 230
TABLE 243 INDIA: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 231
TABLE 244 INDIA: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS,
BY TYPE, 2024–2031 (USD MILLION) 231
TABLE 245 INDIA: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER,
2024–2031 (USD MILLION) 231
TABLE 246 AUSTRALIA: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 233
TABLE 247 AUSTRALIA: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 233
TABLE 248 AUSTRALIA: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY TYPE, 2024–2031 (USD MILLION) 234
TABLE 249 AUSTRALIA: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY,
BY TYPE, 2024–2031 (USD MILLION) 234
TABLE 250 AUSTRALIA: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS,
BY TYPE, 2024–2031 (USD MILLION) 234
TABLE 251 AUSTRALIA: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 235
TABLE 252 AUSTRALIA: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 235
TABLE 253 AUSTRALIA: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS, BY TYPE, 2024–2031 (USD MILLION) 235
TABLE 254 AUSTRALIA: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER,
2024–2031 (USD MILLION) 236
TABLE 255 SOUTH KOREA: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 237
TABLE 256 SOUTH KOREA: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 237
TABLE 257 SOUTH KOREA: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY TYPE, 2024–2031 (USD MILLION) 238
TABLE 258 SOUTH KOREA: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY,
BY TYPE, 2024–2031 (USD MILLION) 238
TABLE 259 SOUTH KOREA: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION) 238
TABLE 260 SOUTH KOREA: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 239
TABLE 261 SOUTH KOREA: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 239
TABLE 262 SOUTH KOREA: WEARABLES IN PHARMA & BIOTECH MARKET FOR
CLINICAL TRIALS, BY TYPE, 2024–2031 (USD MILLION) 239
TABLE 263 SOUTH KOREA: WEARABLES IN PHARMA & BIOTECH MARKET,
BY END USER, 2024–2031 (USD MILLION) 240
TABLE 264 REST OF ASIA PACIFIC: WEARABLES IN PHARMA & BIOTECH MARKET,
BY PRODUCT, 2024–2031 (USD MILLION) 241
TABLE 265 REST OF ASIA PACIFIC: WEARABLES IN PHARMA & BIOTECH MARKET,
BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 241
TABLE 266 REST OF ASIA PACIFIC: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY TYPE, 2024–2031 (USD MILLION) 242
TABLE 267 REST OF ASIA PACIFIC: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION) 242
TABLE 268 REST OF ASIA PACIFIC: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION) 242
TABLE 269 REST OF ASIA PACIFIC: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 243
TABLE 270 REST OF ASIA PACIFIC: WEARABLES IN PHARMA & BIOTECH MARKET,
BY APPLICATION, 2024–2031 (USD MILLION) 243
TABLE 271 REST OF ASIA PACIFIC: WEARABLES IN PHARMA & BIOTECH MARKET
FOR CLINICAL TRIALS, BY TYPE, 2024–2031 (USD MILLION) 243
TABLE 272 REST OF ASIA PACIFIC: WEARABLES IN PHARMA & BIOTECH MARKET,
BY END USER, 2024–2031 (USD MILLION) 244
TABLE 273 LATIN AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 244
TABLE 274 LATIN AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 245
TABLE 275 LATIN AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 245
TABLE 276 LATIN AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY TYPE, 2024–2031 (USD MILLION) 246
TABLE 277 LATIN AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY,
BY TYPE, 2024–2031 (USD MILLION) 246
TABLE 278 LATIN AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION) 247
TABLE 279 LATIN AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 247
TABLE 280 LATIN AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 248
TABLE 281 LATIN AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS, BY TYPE, 2024–2031 (USD MILLION) 248
TABLE 282 LATIN AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER, 2024–2031 (USD MILLION) 248
TABLE 283 BRAZIL: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 249
TABLE 284 BRAZIL: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 250
TABLE 285 BRAZIL: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR,
BY TYPE, 2024–2031 (USD MILLION) 250
TABLE 286 BRAZIL: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY,
BY TYPE, 2024–2031 (USD MILLION) 251
TABLE 287 BRAZIL: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS,
BY TYPE, 2024–2031 (USD MILLION) 251
TABLE 288 BRAZIL: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 251
TABLE 289 BRAZIL: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 252
TABLE 290 BRAZIL: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS,
BY TYPE, 2024–2031 (USD MILLION) 252
TABLE 291 BRAZIL: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER,
2024–2031 (USD MILLION) 252
TABLE 292 MEXICO: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 253
TABLE 293 MEXICO: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 254
TABLE 294 MEXICO: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR,
BY TYPE, 2024–2031 (USD MILLION) 254
TABLE 295 MEXICO: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION) 255
TABLE 296 MEXICO: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS,
BY TYPE, 2024–2031 (USD MILLION) 255
TABLE 297 MEXICO: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 255
TABLE 298 MEXICO: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 256
TABLE 299 MEXICO: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS,
BY TYPE, 2024–2031 (USD MILLION) 256
TABLE 300 MEXICO: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER,
2024–2031 (USD MILLION) 256
TABLE 301 REST OF LATIN AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET,
BY PRODUCT, 2024–2031 (USD MILLION) 257
TABLE 302 REST OF LATIN AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET,
BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 258
TABLE 303 REST OF LATIN AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY TYPE, 2024–2031 (USD MILLION) 258
TABLE 304 REST OF LATIN AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET
FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION) 259
TABLE 305 REST OF LATIN AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION) 259
TABLE 306 REST OF LATIN AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 259
TABLE 307 REST OF LATIN AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET,
BY APPLICATION, 2024–2031 (USD MILLION) 260
TABLE 308 REST OF LATIN AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET
FOR CLINICAL TRIALS, BY TYPE, 2024–2031 (USD MILLION) 260
TABLE 309 REST OF LATIN AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET,
BY END USER, 2024–2031 (USD MILLION) 260
TABLE 310 MIDDLE EAST & AFRICA: WEARABLES IN PHARMA & BIOTECH MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 261
TABLE 311 MIDDLE EAST & AFRICA: WEARABLES IN PHARMA & BIOTECH MARKET,
BY PRODUCT, 2024–2031 (USD MILLION) 262
TABLE 312 MIDDLE EAST & AFRICA: WEARABLES IN PHARMA & BIOTECH MARKET,
BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 262
TABLE 313 MIDDLE EAST & AFRICA: WEARABLES IN PHARMA & BIOTECH MARKET
FOR CARDIOVASCULAR, BY TYPE, 2024–2031 (USD MILLION) 263
TABLE 314 MIDDLE EAST & AFRICA: WEARABLES IN PHARMA & BIOTECH MARKET
FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION) 263
TABLE 315 MIDDLE EAST & AFRICA: WEARABLES IN PHARMA & BIOTECH MARKET
FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION) 263
TABLE 316 MIDDLE EAST & AFRICA: WEARABLES IN PHARMA & BIOTECH MARKET
FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 264
TABLE 317 MIDDLE EAST & AFRICA: WEARABLES IN PHARMA & BIOTECH MARKET,
BY APPLICATION, 2024–2031 (USD MILLION) 264
TABLE 318 MIDDLE EAST & AFRICA: WEARABLES IN PHARMA & BIOTECH MARKET
FOR CLINICAL TRIALS, BY TYPE, 2024–2031 (USD MILLION) 264
TABLE 319 MIDDLE EAST & AFRICA: WEARABLES IN PHARMA & BIOTECH MARKET,
BY END USER, 2024–2031 (USD MILLION) 265
TABLE 320 GCC: WEARABLES IN PHARMA & BIOTECH MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 265
TABLE 321 GCC: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 266
TABLE 322 GCC: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 266
TABLE 323 GCC: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR,
BY TYPE, 2024–2031 (USD MILLION) 267
TABLE 324 GCC: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY,
BY TYPE, 2024–2031 (USD MILLION) 267
TABLE 325 GCC: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS,
BY TYPE, 2024–2031 (USD MILLION) 267
TABLE 326 GCC: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 268
TABLE 327 GCC: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 268
TABLE 328 GCC: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS,
BY TYPE, 2024–2031 (USD MILLION) 268
TABLE 329 GCC: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER,
2024–2031 (USD MILLION) 269
TABLE 330 SAUDI ARABIA: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 270
TABLE 331 SAUDI ARABIA: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 270
TABLE 332 SAUDI ARABIA: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY TYPE, 2024–2031 (USD MILLION) 271
TABLE 333 SAUDI ARABIA: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY,
BY TYPE, 2024–2031 (USD MILLION) 271
TABLE 334 SAUDI ARABIA: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION) 271
TABLE 335 SAUDI ARABIA: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 272
TABLE 336 SAUDI ARABIA: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 272
TABLE 337 SAUDI ARABIA: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS, BY TYPE, 2024–2031 (USD MILLION) 272
TABLE 338 SAUDI ARABIA: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER, 2024–2031 (USD MILLION) 273
TABLE 339 UAE: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 274
TABLE 340 UAE: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 274
TABLE 341 UAE: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR,
BY TYPE, 2024–2031 (USD MILLION) 275
TABLE 342 UAE: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY,
BY TYPE, 2024–2031 (USD MILLION) 275
TABLE 343 UAE: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS,
BY TYPE, 2024–2031 (USD MILLION) 275
TABLE 344 UAE: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 276
TABLE 345 UAE: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 276
TABLE 346 UAE: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS,
BY TYPE, 2024–2031 (USD MILLION) 276
TABLE 347 UAE: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER,
2024–2031 (USD MILLION) 277
TABLE 348 REST OF GCC: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 278
TABLE 349 REST OF GCC: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 278
TABLE 350 REST OF GCC: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY TYPE, 2024–2031 (USD MILLION) 279
TABLE 351 REST OF GCC: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY,
BY TYPE, 2024–2031 (USD MILLION) 279
TABLE 352 REST OF GCC: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION) 279
TABLE 353 REST OF GCC: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 280
TABLE 354 REST OF GCC: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 280
TABLE 355 REST OF GCC: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS, BY TYPE, 2024–2031 (USD MILLION) 280
TABLE 356 REST OF GCC: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER,
2024–2031 (USD MILLION) 281
TABLE 357 SOUTH AFRICA: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 282
TABLE 358 SOUTH AFRICA: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 282
TABLE 359 SOUTH AFRICA: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY TYPE, 2024–2031 (USD MILLION) 283
TABLE 360 SOUTH AFRICA: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY,
BY TYPE, 2024–2031 (USD MILLION) 283
TABLE 361 SOUTH AFRICA: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION) 283
TABLE 362 SOUTH AFRICA: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 284
TABLE 363 SOUTH AFRICA: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 284
TABLE 364 SOUTH AFRICA: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS, BY TYPE, 2024–2031 (USD MILLION) 284
TABLE 365 SOUTH AFRICA: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER, 2024–2031 (USD MILLION) 285
TABLE 366 REST OF MIDDLE EAST & AFRICA: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 286
TABLE 367 REST OF MIDDLE EAST & AFRICA: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 286
TABLE 368 REST OF MIDDLE EAST & AFRICA: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY TYPE, 2024–2031 (USD MILLION) 287
TABLE 369 REST OF MIDDLE EAST & AFRICA: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION) 287
TABLE 370 REST OF MIDDLE EAST & AFRICA: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION) 287
TABLE 371 REST OF MIDDLE EAST & AFRICA: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 288
TABLE 372 REST OF MIDDLE EAST & AFRICA: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 288
TABLE 373 REST OF MIDDLE EAST & AFRICA: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS, BY TYPE, 2024–2031 (USD MILLION) 289
TABLE 374 REST OF MIDDLE EAST & AFRICA: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER, 2024–2031 (USD MILLION) 289
TABLE 375 STRATEGIES ADOPTED BY KEY PLAYERS IN WEARABLES IN PHARMA & BIOTECH MARKET, 2023–2026 290
TABLE 376 WEARABLES IN PHARMA & BIOTECH MARKET: DEGREE OF COMPETITION 293
TABLE 377 REGION FOOTPRINT 300
TABLE 378 PRODUCT FOOTPRINT 301
TABLE 379 THERAPEUTIC AREA FOOTPRINT 302
TABLE 380 APPLICATION FOOTPRINT 303
TABLE 381 END USER FOOTPRINT 304
TABLE 382 LIST OF START-UPS/SMES 307
TABLE 383 COMPETITIVE BENCHMARKING OF START-UPS/SMES 307
TABLE 384 WEARABLES IN PHARMA & BIOTECH MARKET: PRODUCT LAUNCHES AND APPROVALS, 2023–2026 308
TABLE 385 WEARABLES IN PHARMA & BIOTECH MARKET: DEALS, 2023–2026 309
TABLE 386 WEARABLES IN PHARMA & BIOTECH MARKET: OTHER DEVELOPMENTS,
2023–2026 309
TABLE 387 DEXCOM, INC.: COMPANY OVERVIEW 310
TABLE 388 DEXCOM, INC.: PRODUCTS OFFERED 311
TABLE 389 DEXCOM, INC.: PRODUCT LAUNCHES AND APPROVALS 312
TABLE 390 DEXCOM, INC.: DEALS 312
TABLE 391 ABBOTT: COMPANY OVERVIEW 315
TABLE 392 ABBOTT: PRODUCTS OFFERED 316
TABLE 393 ABBOTT: PRODUCT LAUNCHES AND APPROVALS 317
TABLE 394 ABBOTT: DEALS 318
TABLE 395 ABBOTT: OTHER DEVELOPMENTS 318
TABLE 396 MASIMO: COMPANY OVERVIEW 320
TABLE 397 MASIMO: PRODUCTS OFFERED 321
TABLE 398 MASIMO: PRODUCT LAUNCHES AND APPROVALS 322
TABLE 399 MASIMO: DEALS 323
TABLE 400 BD: COMPANY OVERVIEW 325
TABLE 401 BD: PRODUCTS OFFERED 326
TABLE 402 BD: PRODUCT LAUNCHES AND APPROVALS 327
TABLE 403 BD: DEALS 327
TABLE 404 APPLE INC.: COMPANY OVERVIEW 329
TABLE 405 APPLE INC.: PRODUCTS OFFERED 330
TABLE 406 APPLE INC.: PRODUCT LAUNCHES AND APPROVALS 331
TABLE 407 APPLE INC.: DEALS 331
TABLE 408 BOSTON SCIENTIFIC CORPORATION: COMPANY OVERVIEW 333
TABLE 409 BOSTON SCIENTIFIC CORPORATION: PRODUCTS OFFERED 334
TABLE 410 BOSTON SCIENTIFIC CORPORATION: DEALS 335
TABLE 411 IRHYTHM TECHNOLOGIES, INC.: COMPANY OVERVIEW 336
TABLE 412 IRHYTHM TECHNOLOGIES, INC.: PRODUCTS OFFERED 337
TABLE 413 IRHYTHM TECHNOLOGIES, INC.: PRODUCT LAUNCHES AND APPROVALS 338
TABLE 414 IRHYTHM TECHNOLOGIES, INC.: DEALS 338
TABLE 415 KONINKLIJKE PHILIPS N.V.: COMPANY OVERVIEW 339
TABLE 416 KONINKLIJKE PHILIPS N.V.: PRODUCTS OFFERED 340
TABLE 417 KONINKLIJKE PHILIPS N.V.: PRODUCT LAUNCHES AND APPROVALS 341
TABLE 418 KONINKLIJKE PHILIPS N.V.: DEALS 341
TABLE 419 KONINKLIJKE PHILIPS N.V.: OTHER DEVELOPMENTS 342
TABLE 420 MEDTRONIC: COMPANY OVERVIEW 343
TABLE 421 MEDTRONIC: PRODUCTS OFFERED 344
TABLE 422 MEDTRONIC: DEALS 345
TABLE 423 BIOINTELLISENSE, INC.: COMPANY OVERVIEW 346
TABLE 424 BIOINTELLISENSE, INC.: PRODUCTS OFFERED 347
TABLE 425 BIOINTELLISENSE, INC.: PRODUCT LAUNCHES AND APPROVALS 347
TABLE 426 BIOINTELLISENSE, INC.: DEALS 348
TABLE 427 F. HOFFMANN-LA ROCHE LTD: COMPANY OVERVIEW 349
TABLE 428 F. HOFFMANN-LA ROCHE LTD: PRODUCTS OFFERED 350
TABLE 429 F. HOFFMANN-LA ROCHE LTD: PRODUCT LAUNCHES AND APPROVALS 351
TABLE 430 GE HEALTHCARE: COMPANY OVERVIEW 352
TABLE 431 GE HEALTHCARE: PRODUCTS OFFERED 353
TABLE 432 GE HEALTHCARE: PRODUCT LAUNCHES AND APPROVALS 354
TABLE 433 GE HEALTHCARE: DEALS 354
TABLE 434 BIOBEAT: COMPANY OVERVIEW 355
TABLE 435 BIOBEAT: PRODUCTS OFFERED 355
TABLE 436 BIOBEAT: PRODUCT LAUNCHES AND APPROVALS 356
TABLE 437 BIOBEAT: DEALS 357
TABLE 438 BIOBEAT: OTHER DEVELOPMENTS 357
TABLE 439 EMPATICA INC.: COMPANY OVERVIEW 358
TABLE 440 EMPATICA INC.: PRODUCTS OFFERED 359
TABLE 441 EMPATICA INC.: PRODUCT LAUNCHES AND APPROVALS 359
TABLE 442 EMPATICA INC.: DEALS 360
TABLE 443 VITALCONNECT: COMPANY OVERVIEW 361
TABLE 444 VITALCONNECT: PRODUCTS OFFERED 361
TABLE 445 VITALCONNECT: DEALS 362
TABLE 446 VITALCONNECT: OTHER DEVELOPMENTS 362
TABLE 447 AMETRIS, LLC: COMPANY OVERVIEW 363
TABLE 448 AMETRIS, LLC: PRODUCTS OFFERED 363
TABLE 449 AMETRIS, LLC: DEALS 364
TABLE 450 ALIVECOR, INC.: COMPANY OVERVIEW 366
TABLE 451 ALIVECOR, INC.: PRODUCTS OFFERED 366
TABLE 452 ALIVECOR, INC.: PRODUCT LAUNCHES AND APPROVALS 367
TABLE 453 ALIVECOR, INC.: DEALS 368
TABLE 454 WITHINGS: COMPANY OVERVIEW 369
TABLE 455 WITHINGS: PRODUCTS OFFERED 370
TABLE 456 WITHINGS: PRODUCT LAUNCHES AND APPROVALS 370
TABLE 457 WITHINGS: DEALS 371
TABLE 458 VIVALNK, INC.: COMPANY OVERVIEW 372
TABLE 459 VIVALNK, INC.: PRODUCTS OFFERED 372
TABLE 460 VIVALNK, INC.: PRODUCT LAUNCHES AND APPROVALS 373
TABLE 461 MEDIBIOSENSE: COMPANY OVERVIEW 374
TABLE 462 MEDIBIOSENSE: PRODUCTS OFFERED 374
TABLE 463 MEDIBIOSENSE: PRODUCT LAUNCHES AND APPROVALS 375
TABLE 464 SIBEL HEALTH, INC.: COMPANY OVERVIEW 376
TABLE 465 BYTEFLIES: COMPANY OVERVIEW 376
TABLE 466 STRADOS LABS: COMPANY OVERVIEW 377
TABLE 467 ONERA TECHNOLOGIES B.V.: COMPANY OVERVIEW 377
TABLE 468 EPICORE BIOSYSTEMS, INC.: COMPANY OVERVIEW 378

LIST OF FIGURES

FIGURE 1 MARKET SCENARIO 43
FIGURE 2 GLOBAL WEARABLES IN PHARMA & BIOTECH MARKET, 2024–2031 44
FIGURE 3 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN WEARABLES IN
PHARMA & BIOTECH MARKET 44
FIGURE 4 DISRUPTIONS INFLUENCING GROWTH OF WEARABLES IN
PHARMA & BIOTECH MARKET 45
FIGURE 5 HIGH-GROWTH SEGMENTS IN WEARABLES IN PHARMA & BIOTECH MARKET 46
FIGURE 6 ASIA PACIFIC TO BE FASTEST-GROWING REGION DURING FORECAST PERIOD 47
FIGURE 7 EXPANSION OF DECENTRALIZED AND REMOTE PATIENT-CENTRIC TRIALS
TO DRIVE MARKET 48
FIGURE 8 PHARMACEUTICAL & BIOTECH COMPANIES AND US ACCOUNTED FOR LARGEST SHARES IN 2025 49
FIGURE 9 INDIA TO EXHIBIT FASTEST GROWTH DURING FORECAST PERIOD 50
FIGURE 10 PORTER’S FIVE FORCES ANALYSIS 59
FIGURE 11 SUPPLY CHAIN ANALYSIS 63
FIGURE 12 ECOSYSTEM ANALYSIS 64
FIGURE 13 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 70
FIGURE 15 PATENT PUBLICATION TRENDS, 2015–2026 82
FIGURE 16 JURISDICTION AND TOP APPLICANT ANALYSIS 82
FIGURE 17 PATENT ANALYSIS 83
FIGURE 18 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER 97
FIGURE 19 KEY BUYING CRITERIA, BY END USER 98
FIGURE 20 NORTH AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET SNAPSHOT 170
FIGURE 21 ASIA PACIFIC: WEARABLES IN PHARMA & BIOTECH MARKET SNAPSHOT 214
FIGURE 22 REVENUE ANALYSIS OF KEY PLAYERS, 2021–2025 292
FIGURE 23 MARKET SHARE ANALYSIS OF KEY PLAYERS, 2025 293
FIGURE 24 BRAND/PRODUCT COMPARISON 295
FIGURE 25 FINANCIAL METRICS (EV/EBITDA) 296
FIGURE 26 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK
BETA OF KEY VENDORS 296
FIGURE 27 COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025 298
FIGURE 28 COMPANY FOOTPRINT 299
FIGURE 29 COMPANY EVALUATION MATRIX (START-UPS/SMES), 2025 306
FIGURE 30 DEXCOM, INC.: COMPANY SNAPSHOT 311
FIGURE 31 ABBOTT: COMPANY SNAPSHOT 316
FIGURE 32 MASIMO: COMPANY SNAPSHOT 321
FIGURE 33 BD: COMPANY SNAPSHOT 326
FIGURE 34 APPLE INC.: COMPANY SNAPSHOT 330
FIGURE 35 BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT 334
FIGURE 36 IRHYTHM TECHNOLOGIES, INC.: COMPANY SNAPSHOT 337
FIGURE 37 KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT 340
FIGURE 38 MEDTRONIC: COMPANY SNAPSHOT 344
FIGURE 39 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT 350
FIGURE 40 GE HEALTHCARE: COMPANY SNAPSHOT 353
FIGURE 41 RESEARCH DESIGN 379
FIGURE 42 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 385
FIGURE 43 BOTTOM-UP APPROACH 386
FIGURE 44 TOP-DOWN APPROACH 386
FIGURE 45 CAGR PROJECTIONS FROM ANALYSIS OF MARKET DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 388
FIGURE 46 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 388
FIGURE 47 DATA TRIANGULATION 390

---

---